Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose quadrivalent influenza vaccine in older adults
2022-500657-17-00Phase 4Completed
- Sponsor
- Gentofte Hospital
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of influenza vaccine (quadrivalent, high-dose), Vaxigrip and Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen in influenza (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Hospitalization due to influenza or pneumonia. Started Sep 2022; status: completed.
02
Drugs
influenza vaccine (quadrivalent, high-dose)VaxigripInfluenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2022-500657-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500657-17-00.